Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.53 |
| ▸ | EIF4H | Q15056 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1728369 | 0.88 | GAA (0.54) | SMN1; SMN2GAAALDH1A1PABPC1EIF4H | |
| SCHEMBL3574415 | 0.77 | CYP2C9 (0.60) | SMN1; SMN2GAAALDH1A1TDP1CCR5 | |
| SCHEMBL7301613 | 0.76 | ALDH1A1 (0.74) | SMN1; SMN2GAAHSD17B10ALDH1A1PABPC1 | |
| SCHEMBL1727516 | 0.76 | SMN1; SMN2 (0.79) | SMN1; SMN2ALDH1A1TDP1NPSR1CCR5 | |
| SCHEMBL1728847 | 0.76 | CYP2C9 (0.59) | SMN1; SMN2ALDH1A1CCR5HTTKDM4E | |
| SCHEMBL1727617 | 0.76 | HSD11B1 (0.59) | SMN1; SMN2GAAALDH1A1POLBTDP1 | |
| SCHEMBL357539 | 0.75 | GAA (0.68) | SMN1; SMN2GAAHSD17B10ALDH1A1PABPC1 | |
| SCHEMBL12676716 | 0.75 | GAA (0.59) | SMN1; SMN2GAAHSD17B10ALDH1A1PABPC1 | |
| SCHEMBL1727106 | 0.74 | ALDH1A1 (0.60) | SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL19834778 | 0.74 | GAA (0.55) | SMN1; SMN2GAAHSD17B10ALDH1A1PABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377964-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2013-02-19 | — | — | US | claimed |
| EP-1899324-B1 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE INC (US) | 2011-11-30 | — | — | EP | claimed |
| US-20100249186-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-09-30 | — | — | US | claimed |
| US-7759363-B2 | Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists | THERAVANCE, INC. (US) | 2010-07-20 | — | — | US | claimed |
| US-20060270652-A1 | Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists | THERAVANCE, INC. | 2006-11-30 | — | — | US | claimed |
| US-11254655-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-02-22 | — | — | US | disclosed |
| US-20200283408-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-10 | — | — | US | disclosed |
| US-10696656-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190152951-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-05-23 | — | — | US | disclosed |
| US-10233172-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180237420-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-08-23 | — | — | US | disclosed |
| US-9975877-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-22 | — | — | US | disclosed |
| US-9428489-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150183761-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-07-02 | — | — | US | disclosed |
| US-20130273568-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-8377964-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20100249186-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-09-30 | — | — | US | disclosed |
| US-7759363-B2 | Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists | THERAVANCE, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-20090209582-A1 | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-08-20 | — | — | US | disclosed |
| US-20060270652-A1 | Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists | THERAVANCE, INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233172-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR5A | SMN1; SMN2 2118/4885GAA 3284/4885HSD17B10 3386/4885 |
| US-20180237420-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | SMN1; SMN2 2118/4885GAA 3284/4885HSD17B10 3386/4885 |
| US-20200283408-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | SMN1; SMN2 2118/4885GAA 3284/4885HSD17B10 3386/4885 |
| US-20090209582-A1 | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists | HTR4, HTR1A, HTR5A | SMN1; SMN2 2510/4885GAA 2943/4885HSD17B10 3388/4885 |
| US-20100249186-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | SMN1; SMN2 2118/4885GAA 3284/4885HSD17B10 3386/4885 |
| US-11254655-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR5A | SMN1; SMN2 2118/4885GAA 3284/4885HSD17B10 3386/4885 |
| US-10696656-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR5A | SMN1; SMN2 2118/4885GAA 3284/4885HSD17B10 3386/4885 |
| US-20060270652-A1 | Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists | HTR4, HTR1A, HTR5A | SMN1; SMN2 2098/4885GAA 3510/4885HSD17B10 3489/4885 |
| US-20190152951-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | SMN1; SMN2 2118/4885GAA 3284/4885HSD17B10 3386/4885 |
| US-20150183761-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | SMN1; SMN2 2118/4885GAA 3284/4885HSD17B10 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.